coronavirus
long
known
pathogen
human
anim
apart
caus
communityacquir
coronavirus
novel
form
coronaviru
implic
outbreak
sever
acut
respiratori
syndrom
sar
outbreak
middl
east
respiratori
syndrom
mer
toward
end
decemb
novel
type
coronaviru
identifi
caus
agent
cluster
pneumonia
case
wuhan
citi
china
rapid
spread
within
china
caus
epidem
believ
peak
late
januari
earli
februari
initi
refer
caus
agent
known
sever
acut
respiratori
syndrom
coronaviru
recommend
coronaviru
studi
group
intern
committe
taxonomi
virus
offici
design
coronaviru
diseas
world
health
organ
novel
coronaviru
becam
pandem
march
total
case
count
around
world
increas
everi
day
latest
case
count
found
offici
websit
fall
betacoronaviru
subgenu
similar
sar
coronaviru
use
angiotensinconvert
enzym
receptor
cellular
entri
closest
rna
sequenc
found
similar
bat
coronavirus
unknown
transmiss
human
intermedi
host
bat
could
primari
host
wake
pandem
prevent
measur
break
chain
transmiss
adopt
medic
commun
around
world
also
work
hard
find
effect
prevent
cur
therapi
alreadi
suffer
ill
though
difficult
start
see
excit
result
attempt
seek
therapi
diseas
revisit
medic
sar
mer
epidem
resurfac
context
analysi
full
genom
sequenc
coronaviru
caus
shown
resembl
sar
coronaviru
close
middl
eastern
respiratori
syndrom
mer
coronaviru
sar
coronaviru
outbreak
multipl
attempt
find
effect
treatment
viru
apart
meticul
support
care
expert
could
recommend
specif
treatment
epidem
vast
major
patient
treat
glucocorticoid
receiv
ribavirin
drug
found
immedi
longterm
benefici
effect
glucocorticoid
associ
increas
risk
mortal
deceler
process
viral
clearanc
mer
coronaviru
infect
mortal
benefit
rather
convinc
evid
harm
short
term
long
run
sar
coronaviru
stay
lieu
piec
evid
center
diseas
control
prevent
cdc
recommend
use
glucocorticoid
patient
unless
coexist
compel
indic
use
exacerb
chronic
obstruct
lung
diseas
asthma
ribavirin
nucleosid
analog
broad
antivir
activ
also
use
along
glucocorticoid
high
dose
via
intraven
oral
rout
combat
sar
systemat
review
publish
fail
establish
benefici
effect
ribavirin
prospect
observ
studi
includ
patient
receiv
ribavirin
day
along
glucocorticoid
initi
improv
fever
symptom
pneumonia
resurg
fever
patient
within
mean
day
worsen
respiratori
symptom
day
fortyf
percent
patient
newer
lesion
radiograph
diarrhea
seen
patient
day
medic
use
despit
find
studi
go
repurpos
util
sofosbuvir
ribonucl
acid
rna
depend
rna
polymeras
inhibitor
use
treatment
hepat
c
along
ribavirin
patient
data
sequenc
analyz
model
molecular
dock
studi
shown
abil
sofosbuvir
ribavirin
tightli
bind
sar
rnadepend
rna
polymeras
indic
potenti
use
treatment
patient
data
need
emerg
studi
consid
clinic
use
lopinavir
ritonavir
proteas
inhibitor
use
along
ribavirin
glucocorticoid
openlabel
trial
sar
outbreak
treatment
group
given
lopinavirritonavir
along
ribavirin
corticosteroid
compar
control
arm
patient
treat
ribavirin
glucocorticoid
patient
includ
trial
acut
respiratori
distress
syndrom
due
sar
coronaviru
sever
hypoxemia
death
day
composit
primari
outcom
treatment
group
patient
sever
hypoxemia
death
comparison
hypoxemia
control
group
death
due
absenc
definit
treatment
guidelin
china
intern
exchang
promot
associ
medic
health
care
cpam
issu
guidelin
februari
recommend
use
lopinavirritonavir
along
interferonalpha
nebul
form
antivir
action
recommend
base
weaker
evid
trial
lopinavirritonavir
conduct
adult
patient
hospit
sever
fail
show
benefit
beyond
standard
care
avail
studi
patient
treat
lopinavirritonavir
patient
receiv
standard
medic
care
differ
time
clinic
improv
hazard
ratio
confid
interv
mortal
day
vs
differ
confid
interv
decreas
detect
viral
load
two
arm
notabl
gastrointestin
advers
effect
common
lopinavirritonavir
group
led
patient
stop
medic
buoy
activ
ebola
viru
remdesivir
also
test
reportedli
found
activ
sar
mer
coronavirus
remdesivir
nucleosid
analog
investig
agent
avail
commerci
manufactur
gilead
scienc
inc
foster
citi
california
provid
compassion
use
program
request
treat
physician
requir
institut
involv
random
trial
though
clinic
trial
determin
efficaci
remdesivir
patient
infect
ongo
result
may
expect
april
preclin
trial
shown
signific
activ
coronaviru
invitro
studi
reveal
potent
antivir
activ
remdesivir
chloroquin
hydroxychloroquin
analog
chloroquin
tradit
use
antimalari
agent
diseasemodifi
antirheumat
drug
dmard
condit
like
lupu
rheumatoid
arthriti
hydroxychloroquin
believ
disrupt
vesicl
function
parasit
increas
ph
also
arrest
variou
erythrocyt
stage
plasmodium
exert
antimalari
effect
also
inhibit
acut
phase
reactant
rheumatoid
factor
variou
enzym
immunosuppress
effect
state
council
china
news
brief
februari
releas
first
posit
experi
regard
use
chloroquin
phosphat
patient
pneumonia
multicent
clinic
trial
conduct
differ
hospit
china
per
news
brief
state
council
china
letter
publish
gao
j
et
al
februari
patient
found
lesser
exacerb
pneumonia
due
improv
radiolog
find
better
virusneg
convers
shorter
cours
diseas
chloroquin
phosphat
treatment
arm
comparison
control
group
per
author
chloroquin
recommend
includ
next
edit
offici
guidelin
releas
nation
health
commiss
peopl
republ
china
manag
pneumonia
caus
chines
expert
panel
recommend
chloroquin
mg
twicedaili
dose
day
besid
china
sever
countri
base
upon
benefit
shown
limit
invitro
studi
anecdot
experi
current
use
chloroquin
hydroxychloroquin
patient
pneumonia
march
find
releas
openlabel
studi
investig
use
hydroxychloroquin
azithromycin
hospit
patient
studi
conduct
mediterrane
infect
univers
hospit
institut
marseil
franc
patient
age
year
includ
polymeras
chain
reaction
pcr
techniqu
use
detect
nasopharyng
sampl
patient
admiss
studi
enrol
patient
meet
inclus
criteria
twentysix
patient
receiv
hydroxychloroquin
patient
control
report
six
patient
lost
followup
due
earli
cessat
treatment
studi
includ
asymptomat
patient
patient
upper
respiratori
tract
symptom
urti
lower
respiratori
tract
symptom
lrti
author
confirm
case
lrti
pneumonia
confirm
radiolog
find
comput
tomographi
ct
chest
demograph
factor
treatment
control
arm
wellmatch
except
averag
age
hydroxychloroquinereceiv
patient
year
versu
year
control
group
patient
treatment
arm
administ
mg
oral
hydroxychloroquin
three
time
day
day
control
arm
six
patient
also
receiv
azithromycin
dose
mg
first
day
follow
mg
daili
four
day
prevent
secondari
bacteri
infect
primari
endpoint
virolog
clearanc
sixth
day
initi
treatment
result
studi
reveal
hydroxychloroquinetr
patient
free
viru
compar
patient
control
group
interestingli
six
patient
treat
hydroxychloroquin
azithromycin
cure
one
patient
receiv
hydroxychloroquin
remain
pcrposit
sixth
day
abl
get
rid
viru
ninth
day
addit
azithromycin
eighth
day
also
person
opin
result
studi
promis
especi
current
context
pandem
entir
world
struggl
find
definit
treatment
apart
cure
exist
patient
studi
open
avenu
studi
gear
toward
find
prophylact
regimen
also
stop
emerg
new
case
limit
burden
pandem
howev
acknowledg
studi
limit
due
smaller
sampl
size
restrict
ethnic
geograph
popul
shortterm
followup
also
rais
queri
concern
regard
six
patient
drop
studi
result
look
promis
patient
receiv
combin
hydroxychloroquin
azithromycin
whether
combin
two
medic
lead
potenti
cardiacel
advers
event
ventricular
arrhythmia
mainli
due
risk
qt
prolong
someth
need
address
futur
studi
anoth
question
studi
rais
possibl
exist
certain
resist
strain
respond
hydroxychloroquin
treatment
unit
state
well
clinic
trial
involv
hydroxychloroquin
plan
treatment
mild
moder
sever
also
pre
postexposur
prophylaxi
current
vaccin
approv
preexposur
postexposur
prophylaxi
variou
clinic
trial
conduct
unit
state
countri
postexposur
prophylaxi
unit
state
first
vaccin
evalu
prevent
use
techniqu
would
promot
express
viral
protein
potenti
induc
respons
immun
apparatu
host
entir
world
look
forward
breakthrough
term
vaccin
wait
patient
wake
pandem
caus
medic
scientif
commun
around
world
race
time
find
cure
sudden
onset
unpreced
surg
viru
instil
urgenc
seek
prevent
therapeut
option
recent
outpour
data
rather
smaller
studi
anecdot
experi
consid
major
breakthrough
may
look
silver
line
bigger
studi
need
start
immedi
consolid
data
obtain
smaller
studi
must
make
care
choic
design
larger
studi
base
preliminari
data
smaller
studi
might
risk
treat
patient
therapi
may
ultim
prove
effect
may
also
miss
opportun
pursu
better
option
